1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU Solicits Stakeholder Views On Fairness And Structure Of EMA’s Fee System

 
• By Ian Schofield

Stakeholders finally have a chance to air their views about the European Medicine Agency’s fee and remuneration system, particularly whether it is “fair, cost-based and not unduly complex.” 

Fees
The European Commission wants stakeholders' views on the EMA's fee structure

The European Commission has launched a public consultation to gather views on the strengths and weaknesses of the European Medicines Agency’s system for collecting fees from the pharmaceutical industry for regulatory services and remunerating the regulators that perform those services.

Aimed at all relevant stakeholders, but particularly those with active experience of the fee system, such as the pharmaceutical industry, academia and research organizations, the consultation is the latest...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

EMA Touts Faster Global Post-Approval Changes Via Regulatory Reliance

 
• By Eliza Slawther

The European Medicines Agency says that a regulatory reliance pilot that it is supporting to speed up assessments of post-approval changes appears to be accelerating evaluation timelines in non-EU countries.

UK And US Regulators In Sync On RWD External Control Arms

 
• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, one of which is Vyjuvek, Krystal Biotech's advanced therapy for treating dystrophic epidermolysis bullosa.

More from Geography